Abstract
The pressure for health-care systems to provide more resource-intensive health care and newer more costly therapies is significant, despite limited health-care budgets. As such, demonstration that a new therapy is effective is no longer sufficient to ensure that it is funded within publicly funded health-care systems. The impact of a therapy on health-care costs is also an important consideration for decision makers who must allocate scarce resources. The clinical benefits and costs of a new therapy can be estimated simultaneously using economic evaluation; the strengths and limitations of which are discussed herein. In addition, within this chapter, we discuss the important economic outcomes that can be collected within a clinical trial (alongside the clinical outcome data) enabling consideration of the impact of the therapy on overall resource use, thus enabling performance of an economic evaluation, if the therapy is shown to be effective.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Manns B, Taub K, Donaldson C (2000) Economic evaluation and end-stage renal disease: From basics to bedside. Am J Kid Dis 36:12–28
United States Renal Data System (2013) Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. https://www.usrds.org/atlas13.aspx. Accessed 17 Dec 2019
Hirth RA (2007) The organization and financing of kindey dialysis and transplant care in the United States of America. Int J Health Care Finance Econ 7:301–318
Manns BJ, Mendelssohn DC, Taub KJ (2007) The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ 7:149–169
Manns B, Hemmelgard B, Tonelli M et al (2019) The cost of care for people with chronic kidney disease. Can J Kid Health Dis 6:2054358119835521
Donaldson C, Shackley P, Detels R, Holland WW, McEwan J, Omenn GS (1997) Economic evaluation. Oxford Textbook of Public Health, 3rd edn. Oxford University Press, Oxford, pp 849–870
Manns B, Doig CJ, Lee H et al (2003) Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery. Crit Care Med 31:449–455
Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H (1997) Cost effectiveness of simvastitin treatment to lower cholesterol levels in patients with coronary heart disease. Scand Simvastatin Survival Study Group. N Engl J Med 336:332–336
Lee H, Manns B, Taub K et al (2002) Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kid Dis 40:611–622
Klarenbach S, Tonelly M, Pauly R et al (2014) Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. J Am Soc Nephrol 25:587–594
Chui BK, Manns B, Pannu N et al (2013) Health care costs of peritoneal dialysis technique failure and dialysis modality switching. Am J Kid Dis 61:104–111
Dialysis modalities for the treatment of end-stage kidney disease: a health technology assessment. CADTH March 2017. https://cadth.ca/sites/default/files/pdf/OP0526_Dialysis_Modalities_Science_Report.pdf. Accessed 17 Dec 2019
Fenton SS, Schaubel DE, Desmeules M et al (1997) Hemodialysis versus periotoneal dialysis: a comparison of adjusted mortality rates. Am J Kid Dis 30:334–342
Foley RN, Parfrey PS, Harnett JD et al (1998) Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 9:267–276
Bloembergen WE, Port FK, Mauger EA, Wolfe RA (1995) A comparison of mortality between patients treated with hemodialysis and periotneal dialysis. J Am Soc Nephrol 6:177–183
Collins AJ, Hao W, Xia H et al (1999) Mortality risks of periotoneal dialysis and hemodialysis. Am J Kid Dis 34:1065–1174
Gerard K, Mooney G (1993) QALY league tables: handle with care. Health Econ 2:59–64
Mauskopf J, Rutten F, Schonfeld W (2003) Cost-effectiveness league tables: valuable guidance for decision maker? PharmacoEconomics 21:991–1000
Drummond M, O’Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford
Cameron C, Coyle D, Ur E, Klarenback S (2010) Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. Can Med Assoc J 182:28–34
McIntosh B, Yu C, Lal A et al (2010) Efficacy of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis. Open Med 4:e102–e113
McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D (2009) The ISPOR good practives for quality improvement of cost-effectiveness research task force report. Value Health 12:1086–1099
Drummond MF, Jefferson TO (1996) The BMJ Economic Evaluation Working Party. Guidleines for authors and peer reviewers of economic submissions to the BMJ. Br Med J 313:275–283
Gold R, Seigal J, Russell L, Weinstein M (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
Guidelines for the economic evaluation of health technologies: Canada (2017) 4th ed. Ottawa: CADTH
Donaldson C, Currie G, Mitton C (2002) Cost effectiveness analysis in health care: contraindications. Br Med J 325:891–894
Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 46:473–481
Schwappach DL (2003) Does it matter who you are or what you gain? An experimental study of preferences for resource allocation. Health Econ 12:255–267
Shrive FM, Ghali WA, Lewis S, Donaldson C, Knudtson ML, Manns BJ (2005) Moving beyond the cost per quality-adjusted life year: modelling the budgetary impact and clinical outcomes associated with the use of sirolimus-eluting stents. Can J Cardiol 21:783–787
Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Austrailia, and Canada. JAMA 302:1437–1443
Miners AH, Garau M, Fidan D, Fischer AJ (2005) Comparing estimates of cost effectiveness submitted to the National Institue for Clinical Excellence (NICE) by different orgaisations: retrospective study. Br Med J 330:65
O’Brien B (1996) Economic evaluation of pharmaceuticals. Frankenstein’s monster or vampire of tirals? Med Care 34(12 Suppl):DS99–D108
Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE (2003) Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 348:2092–2102
Tonelli M, Klaarenback S, Jindal K, Manns B (2006) Economic implications of screening strategies in arteriovenous fistulae. Kidney Int 69:2219–2226
Stelfox HT, Hemmelgarn BR, Bagshaw SM et al (2012) Intensive care unit bed availablity and outcomes for hospitalized patients with sudden clinical deterioration. Arch Intern Med 172:467–474
Manns B, Owen WF Jr, Winkelmayer WC, Devereaux PJ, Tonelli M (2006) Surrogate markers in clinical studies: problems solved or created? Am J Kid Dis 48:159–166
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Manns, B.J. (2021). Evidence-Based Decision Making 7: Health Economics in Clinical Research. In: Parfrey, P.S., Barrett, B.J. (eds) Clinical Epidemiology. Methods in Molecular Biology, vol 2249. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1138-8_27
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1138-8_27
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1137-1
Online ISBN: 978-1-0716-1138-8
eBook Packages: Springer Protocols